BB BIOTECH AG
- WKN: A0NFN3
- ISIN: CH0038389992
- Land: Switzerland
Nachricht vom 19.10.2018 | 07:00
BB BIOTECH AG: Investors showed renewed interest in biotech stocks during the third quarter (news with additional features)
DGAP-News: BB BIOTECH AG / Key word(s): Quarter Results
Media release as of October 19, 2018
Interim report of BB Biotech AG as at September 30, 2018
Investors showed renewed interest in biotech stocks during the third quarter
After a lackluster first half, biotech stocks displayed more vitality in the third quarter. BB Biotech's share price advanced 7.8% in CHF. It gained 9.4% in EUR and 8.8% in USD. Net Asset Value (NAV) increased by nearly the same amount, up 7.3% in CHF, 8.9% in EUR and 8.3% in USD. Net profit for the period amounted to CHF 242 million (Q3 2017: CHF 365 million). BB Biotech's inclusion in the SMIM index of stocks bolstered investor demand for its shares and widened the gap (premium) between the stock's NAV and its market price. Further action was taken to realign the portfolio. Smaller and mid-sized firms represent a growing percentage of the portfolio, while the weighting of large cap stocks is declining. The latter segment made an outstanding contribution to portfolio performance in past years, but it is likely to relinquish its status as the sector's preeminent growth driver going forward. Through its active investment style, BB Biotech is increasing its exposure to novel treatment methods and thereby gradually shifting away from small molecule and recombinant protein treatment avenues. Challenging monoclonal antibodies, RNA-based therapeutic agents, and gene and cell-based therapies offer greater potential.
Third quarter developments extended 2018 equity market trends. The US and China ratcheted up rhetoric and trade tariffs, yet the US markets traded higher - the S&P500 gained 7.7% in USD, reaching new highs. European equity markets again lagged the US as Brexit and Italian political uncertainty filled the economic news. So the DAX Index (-0.5% in EUR) and the Euro Stoxx 600 (1.3% in EUR) went sideways. Meanwhile, SMI gains (5.7% in CHF) were driven by investors rotating into defensive stocks.
Currencies did move around consequent to trade tariffs. Weak in the early third quarter, the US dollar recovered once the US Federal Reserve raised interest rates in September.
Healthcare markets performed well in the third quarter after a disappointing first half year. The MSCI World Health Care Index moved up 11.6% in USD. Biotech equities were similar - with the NBI up 11.2% in USD for the same period. Among other healthcare subsectors, life science tools, medtech and service companies were notably strong.
The innovation elements of the drug sector benefited from US policy statements. Both the FDA and its parent HHS took aim at intermediaries in supply chain. Wall Street was relieved (at least for biotech stocks) and capital flowed into the biotech sector in the third quarter for the first time in at least a year. Renewed investor appetite encouraged IPOs and secondary placements. These trends are helpful, but not particularly informative with respect to BB Biotech's strategy. There were no new major M&A activities involving biotech firms during the third quarter.
The sector continued to see short-term investing strategies to the fore. Positive news events precipitated brisk upward trading, whereas arguably minor setbacks led to even more brisk downward trading. Meantime, BB Biotech remains consistently committed to long-term value and the constant rebalancing of its portfolio. Next-generation investment opportunities are remarkable and so its managers have rebalanced large caps into mid and smaller cap companies and moved positively towards new drug modalities and approaches. This rebalance is part of the perpetual active management of portfolio assets and it marks a move away from small molecules and recombinant human proteins to sophisticated monoclonal antibodies, RNA-based therapeutics, gene therapies and cell therapies. Some of these provide long-lasting effects which can improve product performance and economic value relative to older modalities.
BB Biotech Q3 2018 and 9M 2018 performance
The 9-month performance redressed the first half year 2018 performance. The total share price return (16.8% in CHF, 18.4% in EUR and 15.9% in USD) was higher than the portfolio's Net Asset Value return (4.6% in CHF, 7.5% in EUR and 3.9% in USD). The 9-month net gain of CHF 172 mn compares to a gain of CHF 843 mn for the same period in 2017.
The disconnect between share price and NAV growth reflected a continued share price premium throughout the first nine months of the year. The index inclusion of BB Biotech into the SMIM Index (at around 2.6% weight) and the SPI Index (at around 0.3%) on September 24, 2018 increased demand for BB Biotech shares.
Several of the portfolio companies continued to experience a challenging third quarter. Key holdings such as Radius Health, Alnylam and Tesaro failed to keep pace with the biotech indices. The market was disappointed with Alnylam's Onpattro label - and drug launches at Tesaro and Radius Health failed to excite anyone.
New cycle of portfolio re-positioning initiated
Portfolio restructuring planned in the summer is progressing well. The long-term holdings such as Celgene, Gilead and Novo Nordisk, have been historically superb performers for the portfolio. But these bellwethers may no longer lead growth trends. Portfolio re-adjustment therefore began with careful profit-taking throughout the third quarter. Some shares of Regeneron and Neurocrine were also sold for tactical reasons.
Profits were invested in Scholar Rock, a new holding initiated in this reporting period, and added to existing recent positions taken in Argenx, Exelixis and Nektar Therapeutics. Existing positions in Alnylam, Macrogenics, Voyager Therapeutics, Wave Life Sciences and Radius Health were also increased since their market valuations are substantially below intrinsic value. During the third quarter, the remaining positions in Probiodrug and Five Prime Therapeutics were sold off.
The top portfolio positions reflect expectations of significant growth for RNA-based medicines which will transform drug markets. Supporting this view, a post-quarter note should highlight Janssen's enormous investment in RNAi technology at Arrowhead Pharmaceuticals. BB Biotech is also interested in neurology companies which address broad patient populations and companies such as Vertex, which is well established now with winning technologies and products for cystic fibrosis.
Scholar Rock is focused on extracellular activation of growth factors, such as the TGFbeta superfamily. Their lead compound, SRK-015, is a monoclonal antibody targeting proMyostatin and latent myostatin - designed to inhibit myostatin activation and thereby promote muscle growth and function. The initial indication is late onset spinal muscular atrophy (Type 2 and 3) in combination with Spinraza and other therapeutics. Scholar Rock is also focused on (1) TGFβ and (2) BMP6. For the former, the company could disclose a target and lead indication in this area sometime in 2019. For the latter (bone morphogenic peptide-6) which regulates iron, a lead indication in anemia could be announced in 2019.
BB Biotech was 109% invested at the end of the third quarter - a stable level in absolute and relative terms compared to H1 2018, but well above the 102.5% at the beginning of the year.
Milestones for the third quarter
In the third quarter, three new products from portfolio companies received approval and one product application was declined.
Agios reported the FDA approval of Tibsovo (ivosidenib) for the treatment of relapsed or refractory acute myeloid leukemia (AML). Tibsovo is the second IDH mutant inhibitor to be approved and potentially addresses (together with IDHIFA) approximately 20% of all AML patients. In addition to these two approved agents, Agios is advancing a range of pipeline compounds in its three major focus areas: cancer metabolism; rare genetic disorders; and metabolic immune-oncology.
Alnylam achieved approval of Onpattro (patisiran), the world's first commercially available RNAi product. Onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis in adults with polyneuropathy.
Neurocrine, together with its marketing partner AbbVie announced the approval of Orilissa (elagolix) for the management of moderate to severe pain associated with endometriosis. Orilissa is the first and only oral gonadotropin-releasing hormone (GnRH) antagonist approved for endometriosis, a large market opportunity.
Akcea and Ionis received a complete response letter from the FDA for their new drug application for Waylivra (volanesorsen). This rejection was unexpected following a positive FDA advisory panel vote in May 2018. The company is expected to update investors in the coming months on their plans to proceed with Waylivra, once the FDA clarifies their needs. Volanesorsen is also under regulatory review in Europe and Canada.
Outlook for the remaining three months of 2018
The momentum for BB Biotech's portfolio is expected to remain high for the last quarter of 2018 and well into 2019. Multiple late stage clinical trial results and product approvals are expected. As large pharma market capitalizations increase, M&A activity may pick up.
The complete interim report as at September 30, 2018 is available on www.bbbiotech.com.
TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, tel. +41 79 423 22 28
1) Unlisted company
Document title: Press release
|Company:||BB BIOTECH AG|
|Phone:||+41 52 624 08 45|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX|
|End of News||DGAP News Service|
BB Biotech enlarges its Board of Directors
BB BIOTECH AG: Investors showed renewed intere ...
BB Biotech AG reports preliminary results
BB Biotech shares hold steady in the second qu ...
BB Biotech AG reports preliminary results for ...
News im Fokus
Black Pearl Digital AG:
Kapitalerhöhung zur Steigerung des Wachstumstempos
Das Beteiligungs- und Beratungsunternehmen Black Pearl Digital AG spezialisiert sich auf den enorm wachstumsstarken Bereich von Blockchain-Anwendungen für die Finanzindustrie mit dem Ziel diesen Bereich durch die Umsetzung von Blockchain-Architekturen fundamental zu verändern.
Interview im Fokus
„Die Stars sind unser Erfolgsgeheimnis“
Die STARAMBA SE hat den Verkauf der Kryptowährung STARAMBA.Token (STT) erfolgreich abgeschlossen. „Die STT sind ein wesentlicher Baustein unseres wichtigsten Zukunftsprojekts STARAMBA.spaces/MATERIA.ONE“, erläutert STARAMBA-CEO Christian Daudert im Interview mit Financial.de. „Das Produkt MATERIA.ONE hat den großen Vorteil, dass es unendlich skalierbar ist.“ Mit den Erlösen aus dem Token-Sale will STARAMBA „mehr Stars als 3D-Avatare in die VR-Welten bringen und schneller die Userzahlen generieren, die unser VR-Produkt profitabel machen.“
Hohes Kurspotenzial: „Attraktiver „Value-add“-Immobilienspezialist
Die Coreo AG führt derzeit eine Bezugsrechtskapitalerhöhung durch, in deren Rahmen ein Bruttoemissionserlös von bis zu 16 Mio. € angestrebt wird. Der Liquiditätserlös soll zum Erwerb von Gewerbe- und Wohnimmobilien für den Geschäftsbereich „Value Add“ verwendet werden. Derzeit, also pre money, verfügt die Gesellschaft über ein prognostiziertes NAV (auf Grundlage von GBC-Berechnungen) von 2,40 €. Für das laufende und kommende Geschäftsjahr rechnen wir mit einem spürbaren Ertrags- und Ergebnisanstieg. Neben der Steigerung von Mieterträgen sollte die Gesellschaft im nennenswerten Umfang Veräußerungserlöse erzielen sowie stille Reserven aufdecken. Auf Basis unseres DCF-Bewertungsmodells (post money) haben wir ein Kursziel von 3,10 € ermittelt. Auf Basis des aktuellen Kurses sowie des Platzierungspreises im Rahmen der Kapitalerhöhung von 1,60 € je Aktie lautet unserer Einschätzung KAUFEN.“
Der AKTIONÄR News
10. Dezember 07:10 Bayer-Aktie: Monsanto-Ehe vor Scheidung – Jetzt fordert Elliott-Mann ...
10. Dezember 07:05 Wirecard-Aktie: Warum es jetzt auf die 200 ankommt
10. Dezember 07:00 Fresenius-Aktie: Worauf es jetzt nach dem Crash ankommt
10. Dezember 07:00 BASF-Aktie: Das ist ein schlechter Vorbote
10. Dezember 07:00 Deutsche Bank und Commerzbank: Plötzlich wird es wieder spannend
News im Fokus
BASF SE: BASF-Gruppe: Anpassung des Ausblicks für das Geschäftsjahr 2018
07. Dezember 2018, 19:12
9M Results 2018
06. Dezember 2018
Original-Research: Fielmann AG (von Montega AG): Long
07. Dezember 2018